BITS Fellowships for Professional Course candidates
22 June 2026

BITS Fellowships for Professional Course candidates

Post Graduate Degree in Basic Science OR Graduate/Post Graduate in Degree in Professional Course selected through National Eligibility Tests- CSIR –UGC NET including lectureship (Assistant Professorship) and GATE. 
BRIC-NABI requires Life Sciences / Biotechnology research personnel
22 June 2026
BRIC-NABI requires Life Sciences / Biotechnology research personnel
Post graduate degree in any branch of life sciences /biotechnology or Graduate/Post Graduate in any branch of life sciences or biotechnology or Post Graduate in any branch of life sciences /biotechnology selected through National Eligibility Tests-CSIR UGC NET including Lectureship (Assistant Professorship) and GATE.
INTERVIEW FOR PhD August 2026 SESSION at INST Mohali
22 June 2026
INTERVIEW FOR PhD August 2026 SESSION at INST Mohali
A minimum of 60% marks (or CPI of 6.00) at Masters level AND Candidates should have valid GATE/GPAT/CSIR or UGC-NET/JEST/JGEEBILS (TIFR/NCBS)/ICMR-JRF/ICAR-NET/ DBT-JRF/ Project - Funded (as per INST rules)/ DST-INSPIRE will be adhoc basis subject to successful activation of inspire fellowship.
Brainstorming Session Organized by Indian Pharmacopoeia Commission in collaboration with Yashoda Medicity
22 June 2026
Brainstorming Session Organized by Indian Pharmacopoeia Commission in collaboration with Yashoda Medicity

The Govt. of India have created a separate, dedicated, autonomous institution in the form of the Indian Pharmacopoeia Commission (IPC) to deal with matters relating to timely publication of the Indian Pharmacopoeia which is the official book of standards for drug included therein, in terms of the Second Schedule to the Drugs and Cosmetics Act, 1940 so as to specify the standards of identify, purity and strength of the drugs imported, manufactured for sale, stocked or exhibited for sale or distributed in India.

Aurigene looking for Talent Acquisition professional to lead
22 June 2026
Aurigene looking for Talent Acquisition professional to lead
MBA / Postgraduates in HR with 8-10 years of experience in Talent Acquisition, preferably within the Pharmaceutical, Biotechnology, Life sciences, or Healthcare sectors.
Walk In Drive for Pharma and Science candidates in Production, Technology Transfer, QA and QC at USV
22 June 2026
Walk In Drive for Pharma and Science candidates in Production, Technology Transfer, QA and QC at USV
USV Private Limited is a prominent Indian multinational pharmaceutical and biotechnology company founded in 1961, specializing in diabetes and cardiovascular therapeutics
Sun Pharma Hiring Quality Assurance Sr. Officer
22 June 2026
Sun Pharma Hiring Quality Assurance Sr. Officer
To review the complaint investigation, ensure closure, notification to the complainant and ensure the implementation of the CAPA with its effectiveness.
Clinical Research Coordinator Job at HRAPL
22 June 2026
Clinical Research Coordinator Job at HRAPL
Hiring a Clinical Research Coordinator with 2-3 years of experience to manage daily site activities, patient workflows, and accurate documentation. The role requires strong coordination, attention to detail, and strict protocol compliance to ensure smooth, high-quality clinical operations.
Work as Manufacturing In-charge at Sun Pharma
22 June 2026
Work as Manufacturing In-charge at Sun Pharma
To co-ordinate with purchase department for status of purchase order and delivery of consignment from supplier as when required.
Merck’s Tulisokibart Clears Key Phase 3 Hurdle, Raising Hopes for Ulcerative Colitis Patients
22 June 2026
Merck’s Tulisokibart Clears Key Phase 3 Hurdle, Raising Hopes for Ulcerative Colitis Patients

Merck & Co. has announced positive topline results from the Phase 3 ATLAS-UC induction-only study evaluating its investigational anti-TL1A monoclonal antibody tulisokibart in patients with moderately to severely active ulcerative colitis (UC).

According to the company, the study successfully achieved both its primary endpoint and key secondary endpoints, marking an important milestone in the development of a potential new treatment option for patients living with the chronic inflammatory bowel disease.